Free Trial
NASDAQ:AKYA

Akoya Biosciences Q1 2025 Earnings Report

Akoya Biosciences EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Akoya Biosciences Revenue Results

Actual Revenue
$16.64 million
Expected Revenue
$20.19 million
Beat/Miss
Missed by -$3.55 million
YoY Revenue Growth
N/A

Akoya Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
12:00AM ET

Akoya Biosciences Earnings Headlines

AKYA Akoya Biosciences, Inc. - Seeking Alpha
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
See More Akoya Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akoya Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akoya Biosciences and other key companies, straight to your email.

About Akoya Biosciences

Akoya Biosciences (NASDAQ:AKYA), a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

View Akoya Biosciences Profile

More Earnings Resources from MarketBeat